PathoQuest and Charles River Laboratories have signed an expanded global strategic partnership agreement related to PathoQuest’s next generation sequencing (NGS) service solution for the biologics industry. Charles River has provided clients access to PathoQuest’s NGS solution since 2016.
PathoQuest’s Biologics Genomic Service combines a proprietary sample preparation method, state-of-the-art equipment, and an exclusive curated pathogen database with a comprehensive BioIT analysis pipeline. PathoQuest’s solution is a powerful test for identifying adventitious agents in a single, comprehensive analysis that minimizes false negatives while also providing a tool for the genetic characterization of cell lines. The combination of Charles River’s existing GLP and GMP capabilities and PathoQuest’s unique offering allows for a fully integrated, rapid, and reliable solution for the testing of vaccines, biologics, and gene therapy products.
Greg Beattie, Charles River’s Corporate Vice-President for Global Biologics Testing stated “Our partnership with PathoQuest is integral to our ability to provide the most sensitive testing methods to our clients in order to ensure the safety of biological products produced by the biopharmaceutical industry. PathoQuest’s NGS-based testing solution provides a comprehensive analysis that is both rapid and reliable.”
Jean-François Brepson, President and CEO of PathoQuest commented “Industry guidelines increasingly identify High-Throughput Sequencing as a highly sensitive and reliable testing solution. We anticipate Charles River’s global footprint and biologics-industry leadership will enable the further growth and expansion of our platform.”
Click here for more information on Charles River’s biologics testing solutions.
Click here to learn more about PathoQuest’s Biologics Genomic Service for biopharmaceutical companies.